Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women

Lupus

Volumn 26, Issue 9, 2017, Pages 944-951

  Mendoza Pinto, C ^a,b   Garcia Carrasco M ^a,b   Vallejo Ruiz, V ^a   Mendez Martinez S ^a   Taboada Cole, A ^a   Etchegaray Morales, I ^a   Munoz Guarneros M ^b   Reyes Leyva, J ^a   Lopez Colombo A ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

human papillomavirus infection; incidence; prognosis; risk factors; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALPHAPAPILLOMAVIRUS; ARTICLE; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 61; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 72; HUMAN PAPILLOMAVIRUS TYPE 81; HUMAN PAPILLOMAVIRUS TYPE 84; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; OBSERVATIONAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEXUALITY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVICITIS; UTERINE CERVIX CYTOLOGY; VIRAL CLEARANCE; VIRUS DETECTION; COMPLICATION; GENETICS; ISOLATION AND PURIFICATION; MEXICO; MORTALITY; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEXICO; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL PARTNERS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85023186448     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316686708     Document Type: Article

References (34)

1. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-1490.
2. Parikh-Patel A, White RH, Allen M, Cress R,. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008; 19: 887-894.
3. Dreyer L, Faurschou M, Mogensen M, Jacobsen S,. High incidence of potentially virus induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011; 63: 3032-3037.
4. Cibere J, Sibley J, Haga M,. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001; 10: 394-400.
5. Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmunity Rev 2014; 13: 730-735.
6. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
7. Tam LS, Chan AY, Chan PK, Chang AR, Li EK,. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004; 50: 3619-3625.
8. Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007; 57: 619-25.
9. Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012; 21: 365-372.
10. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19: 1485-1491.
11. Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz M, et al. The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus. Clinics 2013; 68: 1475-1480.
12. Tam LS, Chan PK, Ho SC, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study. J Rheumatol 2010; 37: 330-340.
13. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD,. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
14. Huh WK,. Human papillomavirus infection: a concise review of natural history. Obstet Gynecol 2009; 114: 139-143.
15. Vermund SH, Kelley KF, Klein RS, et al. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1991; 165: 392-400.
16. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC,. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-1349.
17. Lee YH, Choe JY, Park SH, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci 2010; 25: 1431-1437.
18. Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 2013; 33: 335-340.
19. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
20. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D,. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
21. Galdman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
22. Salomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
23. Van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Walboomers JM,. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol 1990; 28: 2739-2743.
24. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, McGeer PL,. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res 1998; 82: 1224-1230.
25. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
26. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol, Biomarkers Prev 2003; 12: 485-490.
27. Aguilar-Lemarroy A, Vallejo-Ruiz V, Cortés-Gutiérrez EI, et al. Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: type-specific prevalence and HPV coinfections. J Med Virol 2015; 87: 871-884.
28. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 8813-8824.
29. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL,. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184: 1508-1517.
30. Kawai T, Akira S,. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650.
31. Yu SL, Chan PK, Wong CK, et al. Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R80.
32. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA,. Increased cervical dysplasia in intravenous cyclophosphamide treated patients with SLE: a preliminary study. Lupus 2000; 9: 542-544.
33. Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31: 1763-1767.
34. Tam LS, Chan PK, Ho SC, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011; 63: 269-276.